RENSCHLER MARKUS MD 4
4 · Cyteir Therapeutics, Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
RENSCHLER MARKUS MD
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-02-29$1.69/sh+12,607$21,306→ 1,094,820 total - Exercise/Conversion
Common Stock
2024-02-29$1.20/sh+2,537$3,044→ 1,097,357 total - Exercise/Conversion
Common Stock
2024-03-04$1.69/sh+6,304$10,654→ 1,103,661 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-29−12,607→ 226,952 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (12,607 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-29−2,537→ 0 totalExercise: $1.20From: 2024-02-01Exp: 2030-02-24→ Common Stock (2,537 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-04−6,304→ 220,648 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (6,304 underlying)
Footnotes (1)
- [F1]The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.